克拉斯
胰腺癌
癌症研究
干扰素
下调和上调
信号转导
免疫系统
生物
先天免疫系统
细胞因子
医学
细胞培养
生长抑制
靶向治疗
细胞生长
细胞信号
胰腺肿瘤
细胞
癌症
免疫学
癌细胞
内部收益率1
肿瘤微环境
类有机物
作者
Yehan Zhang,Shijie Tang,Yi Zhang,Jiahui Liu,Xiaohan Shi,Yikai Li,Yunguang Li,Huan Wang,Chaoliang Zhong,Maoyuan Sun,Wenjie Li,Yiqin Zhu,Weiwei Yang,Yun Zhao,Shiwei Guo,Zhongjun Wu,Lin Wang,Gang Jin,Dong Gao
出处
期刊:Cancer Cell
[Cell Press]
日期:2026-10-29
卷期号:44 (11): 2305-2323.e10
被引量:1
标识
DOI:10.1016/j.ccell.2026.10.003
摘要
KRAS G12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRAS G12D -targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRAS G12D -mutant subset intrinsically resistant to KRAS G12D -targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI